Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies

Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multiple myeloma (MM) patients. Genetic and epigenetic mechanisms involved in EMM and the therapeutic role of new agents for MM are not well established. Besides, well-characterized preclinical models for...

Descripción completa

Detalles Bibliográficos
Autores principales: Farre, Lourdes, Sanz, Gabriela, Ruiz-Xivillé, Neus, Castro de Moura, Manuel, Martin-Tejera, Juan Francisco, Gonçalves-Ribeiro, Samuel, Martinez-Iniesta, Maria, Calaf, Monica, Luis Mosquera, Jose, Martín-Subero, José Ignacio, Granada, Isabel, Esteller, Manel, Domingo-Domenech, Eva, Climent, Fina, Villanueva, Alberto, Sureda, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2021
Materias:
Resource Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325009/
https://www.ncbi.nlm.nih.gov/pubmed/33988237
http://dx.doi.org/10.1242/dmm.048223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325009/
https://www.ncbi.nlm.nih.gov/pubmed/33988237
http://dx.doi.org/10.1242/dmm.048223

Ejemplares similares